A Study to Evaluate the Cancer Related Pro-Inflammatory Response as a Stratifying Biomarker of Sorafenib Induced Survival in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 02 Mar 2017 Results published in the Alimentary Pharmacology and Therapeutics.
- 16 May 2016 New trial record
- 17 Apr 2016 Results (N=442) assessing biomarkers to predict sorafenib induced survival benefit presented at The International Liver Congress™ 2016.